ML365

ML365 is a potent (IC50 = 16 nM) and selective (62-fold selective over TASK-3) blocker of the two-pore domain potassium channel K2P3.1 (TASK-1) .1 It also less potently (IC50 = 4.07 µM) blocks the K2P6.1 (TWIK-2) channel resulting in blocking the ATP-induced NLRP3 inflammasome.2 ML365 improved the efficacy of Levetiracetam in chronically epileptic rats.3 It suppressed the release of TNF-α, IL-6, and IL-1ß in an LPS-induced inflammatory model via regulation of NF-kB signaling.4